Cargando…

Immune Therapies for Hematologic Malignancies

Detalles Bibliográficos
Autor principal:	Olnes, Matthew J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829785/ https://www.ncbi.nlm.nih.gov/pubmed/33467389 http://dx.doi.org/10.3390/cancers13020295

Ejemplares similares

Immune Microenvironment in Hematologic Malignancies
por: Arandi, Nargess, et al.
Publicado: (2023)

Molecular-Targeted Therapies for Hematologic Malignancies
por: Bunting, Kevin D., et al.
Publicado: (2012)

Molecular Aspects of Hematological Malignancies and Benign Hematological Disorders
por: Găman, Amelia Maria
Publicado: (2023)

Recent Prospective in CAR T-Based Therapy for Solid and Hematological Malignancies
por: Marei, Hany E., et al.
Publicado: (2023)

Recent Advances in Immune Therapies for Gastric Cancer
por: Olnes, Matthew J., et al.
Publicado: (2021)

Drug Resistance in Hematological Malignancies
por: Auberger, Patrick, et al.
Publicado: (2020)

Nursing in patients with hematological malignancies
por: Geres, Hana, et al.
Publicado: (2020)

Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies
por: Einsele, Hermann, et al.
Publicado: (2020)

Targeted Therapy in Hematological Malignancies: From Basic Research to Clinical Practice
por: Ma, Haiqing, et al.
Publicado: (2015)

The premier statistical report of hematologic malignancies in Korea
por: Kim, Hee-Je
Publicado: (2012)

Dendritic Cell Therapies for Hematologic Malignancies
por: Weinstock, Matthew, et al.
Publicado: (2017)

Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Kapoor, Sargam, et al.
Publicado: (2021)

The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies
por: Einsele, Hermann, et al.
Publicado: (2021)

Targeting immune checkpoints in hematological malignancies
por: Salik, Basit, et al.
Publicado: (2020)

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
por: Wang, Hao, et al.
Publicado: (2019)

Drug Resistance in Hematologic Malignancies: Induction Mechanisms, Genetics, and Therapeutics
por: Zhan, Fenghuang, et al.
Publicado: (2015)

Accuracy of diagnosis and individualization of treatment: the way of treating hematologic malignancies
por: Liu, Dai-Hong
Publicado: (2020)

Preface of the Special Issue “COVID-19 Infection and Hematological Malignancies”
por: Chen, Mingyi, et al.
Publicado: (2022)

Chromosomal aberrations in hematological malignancies: A guide to the identification of novel oncogenes
por: Vundinti, Babu Rao, et al.
Publicado: (2011)

CXCR4 antagonists in hematologic malignancies: more than just mobilizers?
por: Jo, Deog-Yeon
Publicado: (2011)

For older adults with hematologic malignancies, a comprehensive geriatric assessment matters
por: Cordoba, Raul
Publicado: (2022)

Patients with hematological malignancies admitted to intensive care units: new challenges for the intensivist
por: Torres, Viviane Bogado Leite, et al.
Publicado: (2015)

An interview with Dan L. Longo, Section Editor of the Malignant hematological diseases section
por: Longo, Dan L
Publicado: (2013)

Beyond SARS-CoV2, the role of viruses in the pathogenesis of hematologic malignancies
por: Wiestner, Adrian
Publicado: (2022)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

The journey of CAR-T therapy in hematological malignancies
por: Lu, Junru, et al.
Publicado: (2022)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

The Hematology of Tomorrow Is Here—Preclinical Models Are Not: Cell Therapy for Hematological Malignancies
por: Arranz, Lorena
Publicado: (2022)

Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies
por: Reagan, John L., et al.
Publicado: (2012)

Erratum to: CAR T Cell Therapy for Hematological Malignancies
por: Yang, Xin, et al.
Publicado: (2021)

Emerging Metabolic Targets in the Therapy of Hematological Malignancies
por: Leni, Zaira, et al.
Publicado: (2013)

Immunogenic Cell Death in Hematological Malignancy Therapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplished—What is Next?
por: Gribben, John G., et al.
Publicado: (2020)

Dilemma Concerning the Differential Diagnosis of Hematological Malignancy and Bone Metastasis Arising from Lung Cancer
por: Kaira, Kyoichi
Publicado: (2022)

Reprogramming Tumor-Immune Cell Interface in Solid and Hematological Malignancies to Enhance Response to Therapy
por: Di Martino, Maria Teresa, et al.
Publicado: (2018)

Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy
por: Lang, Yue, et al.
Publicado: (2023)

Unanswered Questions in HIV Hematology
por: Leitch, Heather A., et al.
Publicado: (2012)

Hematologic malignancies following immune checkpoint inhibition for solid tumors
por: van Eijs, Mick J. M., et al.
Publicado: (2022)

Clinical Hematology International: Why a New Journal in Hematology?
por: Mohty, Mohamad, et al.
Publicado: (2019)

Bite-size introduction to canine hematologic malignancies
por: Atherton, Matthew J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t0d4i0daftgks59ltg0fpkjope